At Latus Bio, we are developing CNS gene therapy candidates, using proprietary technologies that have been used to identify and engineer novel adeno-associated virus (AAV) capsid variants with the aim of showing unprecedented potency, specificity, and safety. We are honored to attend this year's American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore, MD, May 7 – 11, 2024. Latus will be hosting a Speaker Showcase on May 7th from 5pm to 6:30 pm at the Baltimore Convention Center in Room 343 to explore the challenges, opportunities and goals for gene therapy programs in CNS. We are joined by our illustrious guest speakers: Beverly Davidson, Children’s Hospital of Philadelphia and Latus SAB Chair Sarah Tabrizi, University College of London Rebecca Ahrens-Nicklas, Children’s Hospital of Philadelphia Angela Schulz, University Medical Center Hamburg-Eppendorf Further, Latus co-founder Professor Beverly Davidson will be a conference keynote speaker on May 9th. Her address will highlight the Company's progress and the vast potential of its technology to solve unmet needs in CNS gene therapy. We look forward to seeing everyone there. https://lnkd.in/ecDxYCcD
At #ASGCT2024, Beverly Davidson, PhD, Children's Hospital of Philadelphia Research Institute Chief Scientific Strategy Officer, will present as the Keynote Speaker for the George Stamatoyannopoulos Memorial Lecture in Baltimore, Maryland! An expert in cell and gene therapy research and leader of the Clinical Vector Core (CVC) at Children's Hospital of Philadelphia, Dr. Davidson will speak on "Unlocking the Power of AAVs for Brain Gene Therapies" on May 9. Interested in learning more about the CVC's history of developing and manufacturing viral vectors? Head over to our website: http://ms.spr.ly/6044YpPMu #GeneticDisease #GeneEditing #CellTherapy #GeneTherapy #Vector #ClinicalResearch #ASGCT24